Logo

Bausch Health Initiates Second P-III Study for NOV03 (perfluorohexyloctane) to Treat DED Associated With MGD

Share this

Bausch Health Initiates Second P-III Study for NOV03 (perfluorohexyloctane) to Treat DED Associated With MGD

Shots:

  • The enrollment of the first P-III study is currently underway & has reached 85% of its enrollment goal. In a P-II study of 336 patients- NOV03 met its 1EP of efficacy i.e. improvement of total corneal fluorescein staining over control @8wks.
  • Additionally- NOV03 showed improvement of certain symptoms- such as severity & frequency of dryness & burning/stinging of the eyes- over the entire duration of the P-II study with no notable safety events
  • NOV03 is an investigational- water-free & preservative-free solution- based on patented EyeSol technology from Novaliq

­ Ref: PRNewswire | Image: SPJNews

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions